Speaker: Paul Reading, PhD, Clinical Neurologist, Department of Neurology, Newcastle General Hospital, Newcastle-Upon-Tyne, United Kingdom. Results from an open-exploratory study point out that the cholinesterase inhibitor rivastigmine (Exelon, Novartis) has a positive effect on the neuropsychiatric complications of Parkinson’s disease (PD), particularly hallucinations and sleep disturbances, and significantly enhances cognitive performance without worsening motor control.

Continue reading " American Academy of Neurology: Cholinesterase Inhibitor for Parkinsonian Neuropsychiatric Symptoms "